Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: Results from the SOCRATES retrospective study

Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, Paolo Scollo, Franco Odicino, Gennaro Cormio, Dionyssios Katsaros, Antonella Villa, Liliana Mereu, Fabio Ghezzi, Luigi Manzione, Rossella Lauria, Enrico Breda, Desiderio Gueli Alletti, Michela Ballardini, Alessandra Vernaglia Lombardi, Roberto Sorio, Giorgia Mangili, Domenico Priolo, Giovanna MagniAlessandro Morabito

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. Methods: The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Results: Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04). Median time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023). Conclusion: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy. Studies dedicated to this histological subgroup are needed.

Original languageEnglish
Article number252
JournalBMC Cancer
Volume8
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

Ovarian Neoplasms
Retrospective Studies
Platinum
Recurrence
Drug Therapy
Mucinous Adenocarcinoma
Neoplasms
Neoplasm Grading
Appointments and Schedules
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months : Results from the SOCRATES retrospective study. / Pignata, Sandro; Ferrandina, Gabriella; Scarfone, Giovanna; Scollo, Paolo; Odicino, Franco; Cormio, Gennaro; Katsaros, Dionyssios; Villa, Antonella; Mereu, Liliana; Ghezzi, Fabio; Manzione, Luigi; Lauria, Rossella; Breda, Enrico; Alletti, Desiderio Gueli; Ballardini, Michela; Lombardi, Alessandra Vernaglia; Sorio, Roberto; Mangili, Giorgia; Priolo, Domenico; Magni, Giovanna; Morabito, Alessandro.

In: BMC Cancer, Vol. 8, 252, 01.09.2008.

Research output: Contribution to journalArticle

Pignata, S, Ferrandina, G, Scarfone, G, Scollo, P, Odicino, F, Cormio, G, Katsaros, D, Villa, A, Mereu, L, Ghezzi, F, Manzione, L, Lauria, R, Breda, E, Alletti, DG, Ballardini, M, Lombardi, AV, Sorio, R, Mangili, G, Priolo, D, Magni, G & Morabito, A 2008, 'Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: Results from the SOCRATES retrospective study', BMC Cancer, vol. 8, 252. https://doi.org/10.1186/1471-2407-8-252
Pignata, Sandro ; Ferrandina, Gabriella ; Scarfone, Giovanna ; Scollo, Paolo ; Odicino, Franco ; Cormio, Gennaro ; Katsaros, Dionyssios ; Villa, Antonella ; Mereu, Liliana ; Ghezzi, Fabio ; Manzione, Luigi ; Lauria, Rossella ; Breda, Enrico ; Alletti, Desiderio Gueli ; Ballardini, Michela ; Lombardi, Alessandra Vernaglia ; Sorio, Roberto ; Mangili, Giorgia ; Priolo, Domenico ; Magni, Giovanna ; Morabito, Alessandro. / Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months : Results from the SOCRATES retrospective study. In: BMC Cancer. 2008 ; Vol. 8.
@article{9c100eade2414c3abcfd910ad8b9e850,
title = "Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: Results from the SOCRATES retrospective study",
abstract = "Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. Methods: The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Results: Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20{\%} of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4{\%} vs 62.6{\%}, respectively, p = 0.04). Median time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023). Conclusion: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy. Studies dedicated to this histological subgroup are needed.",
author = "Sandro Pignata and Gabriella Ferrandina and Giovanna Scarfone and Paolo Scollo and Franco Odicino and Gennaro Cormio and Dionyssios Katsaros and Antonella Villa and Liliana Mereu and Fabio Ghezzi and Luigi Manzione and Rossella Lauria and Enrico Breda and Alletti, {Desiderio Gueli} and Michela Ballardini and Lombardi, {Alessandra Vernaglia} and Roberto Sorio and Giorgia Mangili and Domenico Priolo and Giovanna Magni and Alessandro Morabito",
year = "2008",
month = "9",
day = "1",
doi = "10.1186/1471-2407-8-252",
language = "English",
volume = "8",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months

T2 - Results from the SOCRATES retrospective study

AU - Pignata, Sandro

AU - Ferrandina, Gabriella

AU - Scarfone, Giovanna

AU - Scollo, Paolo

AU - Odicino, Franco

AU - Cormio, Gennaro

AU - Katsaros, Dionyssios

AU - Villa, Antonella

AU - Mereu, Liliana

AU - Ghezzi, Fabio

AU - Manzione, Luigi

AU - Lauria, Rossella

AU - Breda, Enrico

AU - Alletti, Desiderio Gueli

AU - Ballardini, Michela

AU - Lombardi, Alessandra Vernaglia

AU - Sorio, Roberto

AU - Mangili, Giorgia

AU - Priolo, Domenico

AU - Magni, Giovanna

AU - Morabito, Alessandro

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. Methods: The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Results: Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04). Median time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023). Conclusion: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy. Studies dedicated to this histological subgroup are needed.

AB - Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. Methods: The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Results: Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04). Median time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023). Conclusion: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy. Studies dedicated to this histological subgroup are needed.

UR - http://www.scopus.com/inward/record.url?scp=52449120593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449120593&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-8-252

DO - 10.1186/1471-2407-8-252

M3 - Article

C2 - 18761742

AN - SCOPUS:52449120593

VL - 8

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 252

ER -